Movement Disorders

Whether it is a standard of care that is practical but not often appreciated or an emerging treatment that can change the landscape of a devastating disease, neurology as a whole is fueled by hope, and that is a gift that keeps on giving.

Plain sulfonamide diuretics was identified as a drug chemical subgroup potentially inversely associated with Parkinson disease risk, while weaker signals included insulin and ß2-adrenergic agonists.

Here's some of what is coming soon to NeurologyLive® this week.

The neurosurgeon at Allegheny Health Network detailed the potential for robotics in neurosurgery over the coming years, and the vast improvements in comfortability during these procedures. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending January 14, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 13, 2023.

Not previously explored, new findings showed links between antiseizure drug prescriptions and incident PD, with trends towards increased risk in those with greater number of prescription issues and multiple AEDs.

DaxibotulinumtoxinA, the first and only peptide formulated neuromodulator, has been shown to be safe and well tolerated in doses of 125 and 250 units, with clinically meaningful effect observed by both patients and clinicians.

Ryan Case, PhD, head of clinical medical affairs at NeuroDerm, spoke about the main findings from the phase 3 BouNDless trial of ND0612 for Parkinson disease.

The virtual care program built by The Ohio State University Wexner Medical Center allows for expanded access to patient care in rural areas, improved decision-making, and hands-on experience for young neurologists.

In addition to improving ON time in patients with Parkinson disease, ND0612 was well tolerated, with only 6.3% of patients randomized to the treatment discontinuing the trial.

A population-based incident of Parkinson disease cases showed patients were more likely to develop PD dementia in 10 years with a lower level of lysosomal enzyme glucocerebrosidase activity.

Here's some of what is coming soon to NeurologyLive® this week.

After 2 months of treatment, findings showed more improvement in anxiety and mental status with acupuncture in patients with Parkinson Disease than those on sham acupuncture.

Neurology News Network for the week ending January 7, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 6, 2023.

Findings from a large-scale trial of adults aged 65 and older with Parkinson disease showed that treatment with pimavanserin was associated with lower risk of mortality than other atypical antipsychotics.

The increased risk of dementia in patients showing early orthostatic hypotension was independent of the presence of concomitant supine hypertension and other factors associated with cognitive impairment.

Data from a cohort of nearly 100 patients with Parkinson disease suggest there are shared nondopaminergic pathogenic mechanisms between depression and postural instability symptoms of the disease.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Patients with high dysautonomia scores showed significantly slower walking speed, decreased cadence, and shorter stride but increased time than the lower scored group in backward gait.

The case-control study identified numerous motor symptoms and signals that are associated with Parkinson disease diagnosis years after they begin to occur.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending December 31, 2022. [WATCH TIME: 3 minutes]

In 2022, these episodes of the Mind Moments® podcast got the most attention from listeners, with this list brought to you as part of NeurologyLive®'s Year in Review.